IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC) Meeting Abstract


Authors: Rudin, C. M.; Salkeni, M. A.; Gutierrez, M.; Hayashi, H.; Thompson, J.; Arca, M.; Hirose, D.; Singh, J.; Turner, J.; Zhang, Y.; Owonikoko, T. K.
Abstract Title: IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)
Meeting Title: ESMO Congress 2024
Journal Title: Annals of Oncology
Volume: 35
Issue: Suppl. 2
Meeting Dates: 2024 Sep 13-17
Meeting Location: Barcelona, Spain
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2024-09-01
Start Page: S1074
Language: English
ACCESSION: WOS:001326612902432
DOI: 10.1016/j.annonc.2024.08.1903
PROVIDER: wos
Notes: Meeting Abstract: 1812TiP -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Charles Rudin
    489 Rudin
Related MSK Work